HILLSIDE, N.J., May 26 /PRNewswire-FirstCall/ -- AgroLabs, Inc., a wholly- owned subsidiary of Integrated BioPharma, Inc. , began selling its proprietary AgroLabs Thai Mangosteen healthful juice supplement at Costco Wholesale Corporation warehouses throughout South Korea in May 2006.
“The Asian countries have proven to be an important market for AgroLabs. We have experienced an increase in sales of more than 30% over the past 12 months, reflecting wide acceptance of our healthful juice supplements throughout the region,” says Kurt E. Cahill, Chief Operating Officer of AgroLabs. “Based on the increased sales volume of all products to date, we anticipate continued expansion of our line at Costco stores throughout Asia,” says Cahill. Costco currently operates 471 warehouses worldwide.
E. Gerald Kay, Chief Executive Officer of INB, added, “AgroLabs continues to expand both domestically and internationally with its liquid, healthful, nutritional products. Our global reach beyond the U.S. now includes Canada, Mexico, Germany, Korea, Japan, Taiwan, United Emirates, Kuwait, Qatar, Oman, Saudi Arabia and Bahrain.
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen and most recently, Acai Extreme Energy. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at http://www.agrolabs.com or by calling (817) 410-2140.
About Integrated BioPharma, Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at http://www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the Company’s financial results can be found in the Company’s Reports filed with the Securities and Exchange Commission.
Integrated BioPharma, Inc.
CONTACT: Dina Masi, CFO, Integrated BioPharma Inc, 1-888-319-6962,d.masi@ibiopharma.com
